BALTIMORE, MD -- (Marketwired) -- 06/19/13 -- Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that based on recent studies, Plandai Biotechnology Inc.'s (OTCQB: PLPL) products could potentially be used to treat high blood pressure and hypertension. Plandai is a developer of highly bioavailable, phytonutrient rich extracts (like EGCG), which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions.
A number of studies have demonstrated that catechins found in green tea, especially ECGC, decreased the narrowing of blood vessels. Angiotensin converting enzyme (ACE), is an enzyme that leads to uncontrolled vascular constriction, causing blood pressure to rise. Drinking green tea can inhibit ACE activity and help reduce blood pressure.
According to The Archives of Internal Medicine, one study noted that drinking green tea daily can lower the risk of high blood pressure, or hypertension. In the eight-year study, 1,500 participants were checked for the development of hypertension. The study found that participants who consumed more than 20 ounces of tea daily lowered their risk of hypertension by 65%. Consuming 4-20 ounces daily showed a 46 percent lower risk and those participants who consumed less than 4 ounces or who did not consume green tea daily had no protection from hypertension.
Plandaí offers Phytofare Catechin Complex, which is processed to deliver a natural, antioxidant-rich product that contains the full range of green tea catechins at a bioavailability level many times that of other products available on the market. Imagine the huge benefits to manufacturers and consumers alike to have the availability to use a highly concentrated product as part of an effort to prevent a multitude of conditions such as hypertension. As Plandai's commercial offerings are released in key markets, both the Company and consumers are clear beneficiaries.
Goldman Small Cap Research articles and reports on Plandai as well as associated disclaimers can be accessed or downloaded in their entirety by visiting www.goldmanresearch.com.
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.
About Plandai Biotechnology, Inc. (OTCQB: PLPL): Plandai Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts, which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing the patented Phytofare extracts in-house allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include food and beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.
Goldman Small Cap Research
Most Popular Stories
- Cape Cod Building Mussel Industry
- Hollywood Eager to Grasp Hispanic Market
- Frightfully Fun Films Return for Halloween
- Sears Denies Store Closings, Layoffs Report
- Microsoft Beats Income Expectations
- Would Soccer Be Richer Without Small Clubs?
- Cloud Lifts Microsoft's Quarterly Results
- Pfizer Approves $11 Billion Buyback Plan
- IS Funded by Black Market Oil Sales, Racketeering
- Weekly Jobless Claims Rise but Remain Low